从“药茅”到“困兽”，片仔癀的成本失控与转型乏力

Core Viewpoint - The company, once thriving on scarcity and brand premium, is now facing deep challenges in its traditional growth model, with its core advantages under pressure from changing market conditions [2] Financial Performance - In the first half of 2025, the company's total revenue decreased by 4.81% year-on-year, while net profit and net profit excluding non-recurring items fell by 16.22% and 17.04% respectively, indicating a significant drop in profit compared to revenue [3] - The second quarter of 2025 saw a 9.79% year-on-year decline in revenue and a dramatic 40.76% drop in net profit [3] Margin and Cost Pressures - The company's gross profit margin for the first half of 2025 was 40.41%, down 4.33 percentage points from 44.74% in the same period of 2024, which is the main reason for the profit decline exceeding revenue decline [4] - The gross profit margin for the core liver disease medication dropped by 10.89 percentage points year-on-year to 52.98%, a significant decrease from 78.79% in 2023 [4] Raw Material Costs - The price of the core raw material, natural cow bile, surged from 650,000 yuan per kilogram in January 2023 to 1,500,000 yuan per kilogram in 2025, an increase of 130.77% [5] - The cost pressure is particularly acute for the An Gong Niu Huang Wan product, which requires approximately 16 kilograms of natural cow bile per 10,000 boxes, leading to a gross profit margin of only 8.94% for this business in the first half of 2025 [5] Pricing Strategy Challenges - The company has implemented multiple price increases, but the price may have reached a "ceiling," with the retail price of its product rising from 102 yuan per piece to 760 yuan per piece over 20 years [7] - The current market price for the product is lower than the official guidance price, indicating a limit to consumer acceptance of high-priced medications [7] Diversification Efforts - The company's diversification into cosmetics and pharmaceutical distribution has not yielded effective results, with the cosmetics business revenue declining over 60% from 2020 to 2025 [11] - The heart and brain medication business also reported a significant revenue drop of 71.04% year-on-year in the first half of 2025, contributing only 1.13% to total revenue [9] Competitive Landscape - The company faces stiff competition in the An Gong Niu Huang Wan market, where it holds a minority stake in the product series, with competitors like Tong Ren Tang dominating the market [10] - The company's new business ventures are struggling, reflecting challenges in brand recognition, channel operation, and product innovation [11][12]